Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/bjh.13656 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cathepsin-D and outcomes in peripartum cardiomyopathy: Results from IPAC.
Am Heart J Plus
January 2025
University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.
Objective: Evaluate the relationship of cathepsin-D (CD) on disease severity and clinical outcomes for women with peripartum cardiomyopathy.
Background: Cathepsin-D is a protease released during oxidative stress that cleaves prolactin (PRL) generating a 16 kDa fragment that is pro-apoptotic, anti-angiogenic, and has been implicated in the pathogenesis of peripartum cardiomyopathy (PPCM).
Methods: In 99 women with newly diagnosed PPCM enrolled in the Investigation in Pregnancy Associated Cardiomyopathy (IPAC) study, CD levels were assessed by ELISA from serum obtained at study entry.
Real-World Outcomes in Patients with Advanced Penile Squamous Cell Carcinoma Receiving Immune Checkpoint Inhibitors: A Single Institution Experience.
J Immunother Precis Oncol
February 2025
Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
Introduction: Advanced penile squamous cell carcinoma (pSCC) is a rare and aggressive malignancy with a poor prognosis and an unmet need for biomarkers. We performed a retrospective evaluation of real-world efficacy, safety outcomes, and baseline inflammatory biomarkers in patients with advanced pSCC treated with immune checkpoint inhibitors (ICIs).
Methods: We performed a retrospective review of patients with advanced pSCC who received ICIs from 2012 to 2023 at the Winship Cancer Institute of Emory University in Atlanta, GA.
Introduction Despite the favorable prognosis of Hodgkin's disease (HD), some patients experience disease recurrence. Therefore, determining recurrence prognostic factors is very crucial to identify patients at risk of early relapse, maintain remission, and improve outcomes. Materials and methods This retrospective cohort study enrolled HD patients at the National Research Institute of Tuberculosis and Lung Disease (NRITLD), Masih Daneshvari Hospital, between January 1, 2002, and June 30, 2018.
View Article and Find Full Text PDFRenal Outcomes With Renin-Angiotensin System Blockers After Unilateral Nephrectomy.
Kidney Int Rep
January 2025
Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Introduction: Despite the benefits of renin-angiotensin system (RAS) blockers, their immediate use after nephrectomy has been limited because of concerns about impaired renal adaptation. We aimed to evaluate the effect of RAS blockers immediately after unilateral nephrectomy on renal adaptation.
Methods: This single-center retrospective cohort study included 580 patients who underwent elective unilateral nephrectomy between 2010 and 2020 and had preexisting hypertension with antihypertensive medications.
Clinical Spectrum and Outcome of Kidney Involvement in Non-Langerhans Histiocytosis.
Kidney Int Rep
January 2025
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Introduction: The aim of this study was to describe the clinical features and treatment responses of Rosai-Dorfman disease (RDD) and Erdheim-Chester disease (ECD) with kidney involvement.
Methods: We retrospectively analyzed patients with RDD and ECD with kidney involvement from 2005 to 2023, evaluating kidney function changes, as well as computed tomography (CT), and metabolic responses.
Results: The study included 4 patients with RDD and 44 with ECD, with median ages of 58 and 51 years, respectively.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!